Abstract 782P
Background
CRS after neoadjuvant chemotherapy (NACT) and gBRCA status predict survival outcomes of women diagnosed with advanced HGSOC. We investigated the correlation between CRS and gBRCA to understand the potential of CRS as an inexpensive biomarker for PARPi therapy.
Methods
Analysis of the OC gBRCA testing database from a tertiary referral centre. Eligible criteria included women with FIGO stage IIIC/IV HGSOC who received NACT and had gBRCA tested between 01/09/2017 and 31/12/2022. Univariable and Multivariable (MV) Cox Proportional-Hazards Models were applied to assess the association between PFS, OS and clinical factors. Two-Proportions Z Test was applied to assess the proportions of CRS1+2 or CRS3 between gBRCA.
Results
536 women were eligible. Mean age 66 years (range 36–89). 139 had FIGO stage IVB HGSOC. 71% received 3-weekly carboplatin with paclitaxel. Median PFS was 14.4 months (95%CI 13.6–15.4) and OS 38.0 months (95%CI 34.8–42.6) in the overall population. Performance status (0–1 vs. 2–4), cytoreductive surgery (Yes vs. No) and gBRCA status (mutant[MT] vs. wild type[WT]) were predictive (PFS) and prognostic (OS) in the overall population (all P<0.05). 363 women underwent delayed primary surgery (DPS) and had a CRS. Of these, 90% received 3–4 cycles of NACT and 96% had optimal (≤1 cm) cytoreduction. In the NACT-DPS group, MV analysis showed that residual disease (≤1 vs. >1 cm), CRS (3 vs. 1+2) and gBRCA status (MT vs. WT) were predictive (PFS) (all P≤0.02). Proportion testing showed women with gBRCA2 were more likely to have CRS3 vs. CRS1+2 than those with gBRCA1 (P=0.008). Women with gBRCA1 (P=0.075) and gBRCA2 (P=0.078) were not more likely to have CRS3 vs. CRS1+2 then those with WT.
Conclusions
We found a correlation between CRS3 and gBRCA2, but not gBRCA1, in women with FIGO stage IIIC/IV HGSOC treated with NACT-DPS. CRS should be evaluated in a prospective study as a predictor of PARPi efficacy.
Table: 782P
CRS | gBRCA1 | gBRCA2 | WT | PFS, months (95%CI) |
1 | 7 | 1 | 60 | 12.1 (11.5–15.7) |
2 | 19 | 9 | 146 | 15.4 (14.4–16.7) |
1+2 | 26 (84%) | 10 (45%) | 206 (66%) | 14.9 (14.0–16.0) |
3 | 5 (16%) | 12 (55%) | 104 (34%) | 22.8 (20.7–27.9) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R.D. Morgan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11